103 related articles for article (PubMed ID: 16287243)
1. Preparation and characterization of a DOTA-lysine-biotin conjugate as an effector molecule for pretargeted radionuclide therapy.
Hainsworth J; Harrison P; Mather SJ
Bioconjug Chem; 2005; 16(6):1468-74. PubMed ID: 16287243
[TBL] [Abstract][Full Text] [Related]
2. Pretargeted radioimmunotherapy in tumored mice using an in vivo 212Pb/212Bi generator.
Su FM; Beaumier P; Axworthy D; Atcher R; Fritzberg A
Nucl Med Biol; 2005 Oct; 32(7):741-7. PubMed ID: 16243650
[TBL] [Abstract][Full Text] [Related]
3. In vivo evaluation of pretargeted 64Cu for tumor imaging and therapy.
Lewis MR; Wang M; Axworthy DB; Theodore LJ; Mallet RW; Fritzberg AR; Welch MJ; Anderson CJ
J Nucl Med; 2003 Aug; 44(8):1284-92. PubMed ID: 12902420
[TBL] [Abstract][Full Text] [Related]
4. Patient-specific dosimetry of pretargeted radioimmunotherapy using CC49 fusion protein in patients with gastrointestinal malignancies.
Shen S; Forero A; LoBuglio AF; Breitz H; Khazaeli MB; Fisher DR; Wang W; Meredith RF
J Nucl Med; 2005 Apr; 46(4):642-51. PubMed ID: 15809487
[TBL] [Abstract][Full Text] [Related]
5. Biological properties of biotin-chelate conjugates for pretargeted diagnosis and therapy with the avidin/biotin system.
Goodwin DA; Meares CF; Osen M
J Nucl Med; 1998 Oct; 39(10):1813-8. PubMed ID: 9776294
[TBL] [Abstract][Full Text] [Related]
6. Biological comparison of 149Pm-, 166Ho-, and 177Lu-DOTA-biotin pretargeted by CC49 scFv-streptavidin fusion protein in xenograft-bearing nude mice.
Lewis MR; Zhang J; Jia F; Owen NK; Cutler CS; Embree MF; Schultz J; Theodore LJ; Ketring AR; Jurisson SS; Axworthy DB
Nucl Med Biol; 2004 Feb; 31(2):213-23. PubMed ID: 15013487
[TBL] [Abstract][Full Text] [Related]
7. Pretargeted radioimmunotherapy with a single-chain antibody/streptavidin construct and radiolabeled DOTA-biotin: strategies for reduction of the renal dose.
Förster GJ; Santos EB; Smith-Jones PM; Zanzonico P; Larson SM
J Nucl Med; 2006 Jan; 47(1):140-9. PubMed ID: 16391198
[TBL] [Abstract][Full Text] [Related]
8. Intraperitoneal pretarget radioimmunotherapy with CC49 fusion protein.
Buchsbaum DJ; Khazaeli MB; Axworthy DB; Schultz J; Chaudhuri TR; Zinn KR; Carpenter M; LoBuglio AF
Clin Cancer Res; 2005 Nov; 11(22):8180-5. PubMed ID: 16299250
[TBL] [Abstract][Full Text] [Related]
9. Biodistribution and dosimetry of pretargeted monoclonal antibody 2D12.5 and Y-Janus-DOTA in BALB/c mice with KHJJ mouse adenocarcinoma.
Lubic SP; Goodwin DA; Meares CF; Song C; Osen M; Hays M
J Nucl Med; 2001 Apr; 42(4):670-8. PubMed ID: 11337558
[TBL] [Abstract][Full Text] [Related]
10. Radioimmunotherapy of A431 xenografted mice with pretargeted B3 antibody-streptavidin and (90)Y-labeled 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid (DOTA)-biotin.
Yao Z; Zhang M; Axworthy DB; Wong KJ; Garmestani K; Park L; Park CW; Mallett RW; Theodore LJ; Yau EK; Waldmann TA; Brechbiel MW; Paik CH; Pastan I; Carrasquillo JA
Cancer Res; 2002 Oct; 62(20):5755-60. PubMed ID: 12384535
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and preliminary biological evaluation of (3-iodobenzoyl)norbiotinamide and ((5-iodo-3-pyridinyl)carbonyl)norbiotinamide: two radioiodinated biotin conjugates with improved stability.
Foulon CF; Alston KL; Zalutsky MR
Bioconjug Chem; 1997; 8(2):179-86. PubMed ID: 9095358
[TBL] [Abstract][Full Text] [Related]
12. Biotin derivatives carrying two chelating DOTA units. Synthesis, in vitro evaluation of biotinidases resistance, avidin binding, and radiolabeling tests.
Pratesi A; Bucelli F; Mori I; Chinol M; Verdoliva A; Paganelli G; Rivieccio V; Gariboldi L; Ginanneschi M
J Med Chem; 2010 Jan; 53(1):432-40. PubMed ID: 19928962
[TBL] [Abstract][Full Text] [Related]
13. Role of biotin-binding affinity in streptavidin-based pretargeted radioimmunotherapy of lymphoma.
Hamblett KJ; Press OW; Meyer DL; Hamlin DK; Axworthy D; Wilbur DS; Stayton PS
Bioconjug Chem; 2005; 16(1):131-8. PubMed ID: 15656584
[TBL] [Abstract][Full Text] [Related]
14. Improved in vivo stability of actinium-225 macrocyclic complexes.
Deal KA; Davis IA; Mirzadeh S; Kennel SJ; Brechbiel MW
J Med Chem; 1999 Jul; 42(15):2988-92. PubMed ID: 10425108
[TBL] [Abstract][Full Text] [Related]
15. (211)At-labeled and biotinylated effector molecules for pretargeted radioimmunotherapy using poly-L- and poly-D-Lysine as multicarriers.
Lindegren S; Karlsson B; Jacobsson L; Andersson H; Hultborn R; Skarnemark G
Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3873S-9S. PubMed ID: 14506185
[TBL] [Abstract][Full Text] [Related]
16. A genetically engineered anti-CD45 single-chain antibody-streptavidin fusion protein for pretargeted radioimmunotherapy of hematologic malignancies.
Lin Y; Pagel JM; Axworthy D; Pantelias A; Hedin N; Press OW
Cancer Res; 2006 Apr; 66(7):3884-92. PubMed ID: 16585217
[TBL] [Abstract][Full Text] [Related]
17. Avidin-biotin system: a small library of cysteine biotinylated derivatives designed for the [99mTc(N)(PNP)]2+ metal fragment.
Bolzati C; Caporale A; Agostini S; Carta D; Cavazza-Ceccato M; Refosco F; Tisato F; Schievano E; Bandoli G
Nucl Med Biol; 2007 Jul; 34(5):511-22. PubMed ID: 17591551
[TBL] [Abstract][Full Text] [Related]
18. Synthesis, pharmacokinetics, and biodistribution of 67GA deferoxamineacetyl-cysteinylbiotin.
Hashmi M; Rosebrough SF
Drug Metab Dispos; 1995 Dec; 23(12):1362-7. PubMed ID: 8689944
[TBL] [Abstract][Full Text] [Related]
19. Doubly radiolabeled liposomes for pretargeted radioimmunotherapy.
Mougin-Degraef M; Bourdeau C; Jestin E; Saï-Maurel C; Bourgeois M; Saëc PR; Thédrez P; Gestin JF; Barbet J; Faivre-Chauvet A
Int J Pharm; 2007 Nov; 344(1-2):110-7. PubMed ID: 17592745
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of a new biotin-DOTA conjugate for pretargeted antibody-guided radioimmunotherapy (PAGRIT).
Urbano N; Papi S; Ginanneschi M; De Santis R; Pace S; Lindstedt R; Ferrari L; Choi S; Paganelli G; Chinol M
Eur J Nucl Med Mol Imaging; 2007 Jan; 34(1):68-77. PubMed ID: 16755333
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
